ADC Therapeutics (ADCT) to Release Earnings on Monday

ADC Therapeutics (NYSE:ADCT) is projected to post its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect ADC Therapeutics to post earnings of ($0.19) per share and revenue of $19.9870 million for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 4, 2026 at 8:30 AM ET.

ADC Therapeutics (NYSE:ADCT) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $23.06 million for the quarter.

ADC Therapeutics Price Performance

Shares of NYSE:ADCT opened at $3.84 on Friday. ADC Therapeutics has a one year low of $1.23 and a one year high of $4.98. The company has a 50 day moving average of $4.04 and a 200-day moving average of $3.96. The stock has a market cap of $487.77 million, a price-to-earnings ratio of -3.20 and a beta of 1.84.

Insider Transactions at ADC Therapeutics

In related news, major shareholder Redmile Group, Llc sold 2,634,506 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $3.28, for a total transaction of $8,641,179.68. Following the completion of the transaction, the insider owned 12,666,731 shares in the company, valued at approximately $41,546,877.68. The trade was a 17.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 5,880,415 shares of company stock worth $19,641,067 in the last ninety days. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in ADC Therapeutics by 31.1% during the third quarter. Russell Investments Group Ltd. now owns 32,502 shares of the company’s stock valued at $130,000 after purchasing an additional 7,701 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in ADC Therapeutics by 25.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company’s stock valued at $166,000 after purchasing an additional 9,537 shares during the period. ExodusPoint Capital Management LP grew its holdings in ADC Therapeutics by 23.6% during the fourth quarter. ExodusPoint Capital Management LP now owns 56,783 shares of the company’s stock valued at $200,000 after purchasing an additional 10,842 shares during the period. Engineers Gate Manager LP acquired a new position in ADC Therapeutics during the fourth quarter valued at approximately $43,000. Finally, MetLife Investment Management LLC grew its holdings in ADC Therapeutics by 65.3% during the fourth quarter. MetLife Investment Management LLC now owns 49,682 shares of the company’s stock valued at $175,000 after purchasing an additional 19,633 shares during the period. Institutional investors and hedge funds own 41.10% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright lifted their price target on shares of ADC Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.